logo-loader
viewCallitas Health Inc

M Pharmaceutical Inc names new interim boss

Interim CEO Brian Keane told investors he welcomed the chance to assist in the transition of the company.

directors_1,_sized.png
Former CEO Mathew Lehman resigned last month.

M Pharmaceutical Inc (CNSX:MQ, OTCMKTS:MPHMF) has named Brian Keane as the company’s interim president and chief executive officer.

Keane told investors he welcomed the chance to assist in the transition of the company, and said he looked forward to focussing on the development of its existing technologies whilst also exploring new growth opportunities.

It comes after the resignation of Mathew Lehman and a decision last month to drop plans to acquire a weight loss drug called orlistat. Before that, in December, Martin Mintchev resigned from his position as chief scientific officer.

In a statement to the market, M Pharmaceuticals’ board told investors: "Brian has the requisite knowledge and capital markets experience to execute M Pharma's technology development plan, raise the necessary capital and explore an acquisition strategy while providing leadership to the management team pending the appointment of a full time CEO".

Keane has more than seventeen years of experience in capital markets, investing and corporate consultancy and has been involved in the restructuring of some 75 different companies.

Quick facts: Callitas Health Inc

Price: - CAD

CSE:LILY
Market: CSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 25/4/19

2 min read